medroxyprogesterone has been researched along with Albright Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bedós, A; Nolla, M; Nolla, R; Ramió, RM | 1 |
| Bergadá, C; Domené, H; Escobar, ME; Gryngarten, M; López, MR; Ropelato, G | 1 |
| Hauffa, BP; Havers, W; Stolecke, H | 1 |
1 review(s) available for medroxyprogesterone and Albright Syndrome
| Article | Year |
|---|---|
[Precocious puberty in the female sex and Von Recklinghausen's neurofibromatosis. Diagnosis and treatment].
Topics: Adolescent; Child; Diagnosis, Differential; Estrogen Antagonists; Female; Fibrous Dysplasia, Polyostotic; Humans; Medroxyprogesterone; Neurofibromatosis 1; Pituitary Neoplasms; Puberty, Precocious; Tuberous Sclerosis | 1983 |
2 other study(ies) available for medroxyprogesterone and Albright Syndrome
| Article | Year |
|---|---|
Persistence of autonomous ovarian activity after discontinuation of therapy for precocious puberty in McCune-Albright syndrome.
Topics: Child; Estradiol; Female; Fibrous Dysplasia, Polyostotic; Follicle Stimulating Hormone; Follow-Up Studies; Humans; Luteinizing Hormone; Medroxyprogesterone; Ovary; Progesterone Congeners; Puberty, Precocious; Ultrasonography | 1997 |
Short-term effects of testolactone compared to other treatment modalities on longitudinal growth and ovarian activity in a girl with McCune-Albright syndrome.
Topics: Androgen Antagonists; Body Height; Bone Development; Combined Modality Therapy; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Female; Fibrous Dysplasia of Bone; Fibrous Dysplasia, Polyostotic; Follow-Up Studies; Humans; Infant; Medroxyprogesterone; Medroxyprogesterone Acetate; Ovarian Cysts; Ovarian Function Tests; Spironolactone; Testolactone | 1987 |